Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Gamma Glutamylcysteine (GGC) in MCI Patients
NCT07583251Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gamma-Glutamylcysteine in Mild Cognitive Impairment (MCI) (3 arms). Primary endpoints: Number of participants with abnormal kidney and liver function tests at 1 month, Number of participants with treatment-related adverse events with one dose of GGC as assessed by CTCAE at 3 months and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
gamma-Glutamylcysteine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07583251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583251.